RestructuringAug 4, 2026, 04:09 PM
Seres Therapeutics Reduces Facilities Costs, Terminates Lease Early
AI Summary
Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement to effect an early termination of one of its leases, significantly reducing ongoing annual facilities costs and materially eliminating primary restoration obligations. The agreement involves surrendering approximately 21,295 rentable square feet and shortening the lease term for the remaining 47,341 square feet to December 31, 2026. As consideration, Seres will pay a $3.85 million termination fee, increase a letter of credit by $2.2 million, and issue common stock valued at $0.5 million.
Key Highlights
- Early termination of lease for approximately 68,636 sq ft of space.
- Surrender of approximately 21,295 rentable square feet effective August 1, 2026.
- Lease term for remaining 47,341 sq ft shortened from 2031 to December 31, 2026.
- Letter of credit increased by approximately $2.2 million (total $3.6 million) for future rent.
- Termination fee of $3.85 million payable by January 4, 2027.
- Equity issuance of 103,520 common shares valued at approximately $0.5 million.
- Elimination of primary restoration obligations for the surrendered premises.
Price Impact
More from MCRB